Relapse on ibrutinib is frequently due to BTK mutations that prevent inhibitor binding and often lead to the development of more aggressive diseases such as relapse/refractory CLL or Richter Transformation (RT) [11,12] from CLL into diffuse large B-cell lymphoma (DLBCL-RT) [13]. This evidence concerns the gene BTK and diffuse large B-cell lymphoma.